Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder Cancer
Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [COHORT]
4 other identifiers
observational
1,600
1 country
1
Brief Summary
RATIONALE: Learning about the long-term effects of dietary, lifestyle, and environmental factors on the risk of cancer progression and recurrence may help the study of bladder cancer in the future. PURPOSE: This clinical trial is studying how dietary, lifestyle, and environmental factors affect patients with early-stage bladder cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2005
CompletedFirst Submitted
Initial submission to the registry
November 2, 2007
CompletedFirst Posted
Study publicly available on registry
November 5, 2007
CompletedJanuary 10, 2014
February 1, 2010
November 2, 2007
January 9, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Recurrence at 5 years
Progression at 5 years
Interventions
Eligibility Criteria
You may qualify if:
- Enrolled on parent protocol CRUK-BCPP-2005-01
- Bladder lesion with cystoscopic characteristics compatible with urothelial cancer or transitional cell carcinoma
- Histologically proven urothelial cancer meeting one of the following criteria:
- Stage Ta (WHO grade 2/3, or grade 1 tumors that are either multifocal or \> 3 cm in size)
- Stage T1 (any grade)
- Stage Tis
You may not qualify if:
- Previous diagnosis of cancer of the urethra, bladder, ureter, or renal pelvis within the 10 years prior to current diagnosis
- PATIENT CHARACTERISTICS:
- Fit for cystoscopy and surgical biopsy/resection
- HIV infection
- Any condition that, in the opinion of the local investigator, might interfere with the safety of the patient or evaluation of the study objectives
- PRIOR CONCURRENT THERAPY:
- Not specified
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Birmingham
Edgbaston, England, B15 2TT, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Maurice Zeegers
University of Birmingham
Study Design
- Study Type
- observational
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
November 2, 2007
First Posted
November 5, 2007
Study Start
December 1, 2005
Last Updated
January 10, 2014
Record last verified: 2010-02